Related Experiment Video
Updated: Jul 11, 2025
15:07
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
Published on: December 28, 2015
26.7K
[CD23 positive, BCL2 rearrangement-negative germinal centre lymphomas]
Thomas Menter1, Leticia Quintanilla-Martinez2
1Pathologie, Institut für Medizinische Genetik und Pathologie, Universitätsspital Basel, Universität Basel, Schönbeinstr. 40, 4031, Basel, Schweiz. thomas.menter@usb.ch.
Pathologie (Heidelberg, Germany)
|November 6, 2023
Summary
A newly identified follicular lymphoma subtype exhibits diffuse growth, CD23 expression, and lacks BCL2 translocation, often presenting with inguinal localization and a favorable prognosis. Genetic analysis reveals frequent STAT6 or SOCS1 mutations in these lymphomas.
Area of Science:
- Hematology
- Oncology
- Pathology
Context:
- Follicular lymphomas are a heterogeneous group of B-cell neoplasms.
- Recent research has identified a distinct subtype with specific morphological and immunophenotypic features.
- This subtype is characterized by diffuse growth, CD23 expression, and absence of BCL2 translocation.
Purpose:
- To delineate and characterize a specific subtype of follicular lymphoma.
- To investigate the morphological, immunophenotypic, and genetic features of this entity.
- To inform the classification and clinical management of these lymphomas.
Summary:
- A distinct follicular lymphoma subtype is characterized by diffuse growth, CD23 positivity, BCL2 rearrangement negativity, and often inguinal localization with a good prognosis.
- Genetic analysis of this subtype reveals a high frequency of STAT6 or SOCS1 mutations.
- The International Consensus Classification (ICC) has provisionally recognized this as CD23 positive, BCL2 rearrangement-negative germinal center lymphoma.
Impact:
- This provisional classification aids in distinguishing this entity from other lymphomas.
- Further research is needed to refine diagnostic criteria, combining morphology, immunohistochemistry, and genetic alterations.
- Improved classification may lead to better clinical characterization and identification of novel therapeutic strategies for this lymphoma subtype.
